Forms

Achondrogenesis Type 1A via the TRIP11 Gene

  • Summary and Pricing
  • Clinical Features and Genetics
  • Citations
  • Methods
  • Ordering/Specimens
Order Kits
TEST METHODS

Sequencing

Test Code TestIndividual Gene PriceCPT Code Copy CPT Codes
1152 TRIP11$1650.00 81479 Add to Order
Targeted Testing

For ordering targeted known variants, please proceed to our Targeted Variants landing page.

Turnaround Time

The great majority of tests are completed within 18 days.

Clinical Sensitivity
Clinical sensitivity is unknown due to the limited number of patients. Analytical sensitivity may be high because all the reported mutations are point mutations which are expected to be detected by sequencing method. No large deletions/insertions have been reported (Smits, P. et al. N Engl J Med 362(3):206-16, 2010).

See More

See Less

Deletion/Duplication Testing via aCGH

Test Code TestIndividual Gene PriceCPT Code Copy CPT Codes
600 TRIP11$690.00 81479 Add to Order
Pricing Comment

# of Genes Ordered

Total Price

1

$690

2

$730

3

$770

4-10

$840

11-30

$1,290

31-100

$1,670

Over 100

Call for quote

Turnaround Time

The great majority of tests are completed within 28 days.

Clinical Sensitivity
Thus far, no large deletions/insertions have been reported in TRIP11 (Smits, P.  et al. N Engl J Med 362(3):206-16, 2010).

See More

See Less

Clinical Features
Achondrogenesis is a group of disorders related to incomplete ossification of bones in the skull, spine and pelvis. Radiographic features include extremely shortened limbs, short ribs and severe pulmonary hypoplasia. Most patients are stillborn or die soon after birth due to respiratory failure (Borochowitz, Z. et al. J Pediatr 112(1):23-31, 1988). Clinically, it is divided into three subtypes: 1A (OMIM# 200600, also called Houston-Harris Type), 1B (OMIM# 600972, also called Fraccaro Type), and 2 (OMIM#200610), which are caused by mutations in TRIP11, SLC26A2 and COL2A1, respectively.
Genetics
Achondrogenesis Type 1A caused by mutations in TRIP11 (Thyroid hormone receptor interactor 11) is inherited in an autosomal recessive manner. GMAP210 protein (Golgi –microtubule-associated protein, GMAP210) coded by the TRIP11 gene is a Golgi apparatus associated protein containing three domains:  a N-terminal Golgi binding domain (exons 1 to 7), a central coiled-coil domain (exons 7 to 17) and a C-terminal microtubule-binding domain (exons 18 to 21). Studies suggested that it plays a role in assembly and maintenance of the Golgi ribbon structure around the centrosome and Golgi network, and is also required for the glycosylation and cellular transport of multiple proteins (Ramos-Morales, F. et al. Biochem J 357(Pt 3): 699-708, 2001;  Rios, R. M et al. Cell 118(3): 323-335, 2004; Smits, P. et al. N Engl J Med 362(3):206-16, 2010). To date, only six unique causative mutations have been identified in achondrogenesis patients. These mutations are four nonsense and two splicing site mutations (Smits, P. et al., 2010).
Testing Strategy
The TRIP11 protein is coded by exons 1 to 21 of the TRIP11 gene on chromosome 14q32.12. Testing involves PCR amplification from genomic DNA and bidirectional Sanger sequencing of the coding exons and ~20 bp of adjacent noncoding sequences.  We will also sequence any single exon (Test#100) or pair of exons (Test#200) in family members of patients with known mutations or to confirm research results.
Indications for Test
Candidates for this test are patients with symptoms consistent with achondrogenesis, and the family members of patients who have known TRIP11 mutations.

Gene

Official Gene Symbol OMIM ID
TRIP11 604505
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT

Disease

Name Inheritance OMIM ID
Achondrogenesis, Type Ia 200600

Related Tests

Name
Achondrogenesis Type 1B (ACG1B) via the SLC26A2 Gene
Achondrogenesis Type II (ACG2)-Hypochondrogenesis via the COL2A1 Gene

CONTACTS

Genetic Counselors
Geneticist
Citations
  • Borochowitz, Z. et al. (1988). “Achondrogenesis type I: delineation of further heterogeneity and identification of two distinct subgroups.” J Pediatr 112(1):23-31. PubMed ID: 3275766
  • Ramos-Morales, F. et al. (2001). “Two splice variants of Golgi microtubule-associated protein of 210 kDa (GMAP-210) differ in their binding to the cis-Golgi network.” Biochem J 357(Pt3): 699-708. PubMed ID: 11463340
  • Rios, R. M. et al. (2004). “GMAP-210 recruits gamma-tubulin complexes to cis-Golgi membranes and is required for Golgi ribbon formation.” Cell 118(3): 323-335. PubMed ID: 15294158
  • Smits, P. et al. (2010). “Lethal skeletal dysplasia in mice and humans lacking the golgin GMAP-210.” N Engl J Med 362(3):206-216. PubMed ID: 20089971
Order Kits
TEST METHODS

Bi-Directional Sanger Sequencing

Test Procedure

Nomenclature for sequence variants was from the Human Genome Variation Society (http://www.hgvs.org).  As required, DNA is extracted from the patient specimen.  PCR is used to amplify the indicated exons plus additional flanking non-coding sequence.  After cleaning of the PCR products, cycle sequencing is carried out using the ABI Big Dye Terminator v.3.0 kit.  Products are resolved by electrophoresis on an ABI 3730xl capillary sequencer.  In most cases, sequencing is performed in both forward and reverse directions; in some cases, sequencing is performed twice in either the forward or reverse directions.  In nearly all cases, the full coding region of each exon as well as 20 bases of non-coding DNA flanking the exon are sequenced.

Analytical Validity

As of March 2016, we compared 17.37 Mb of Sanger DNA sequence generated at PreventionGenetics to NextGen sequence generated in other labs. We detected only 4 errors in our Sanger sequences, and these were all due to allele dropout during PCR. For Proficiency Testing, both external and internal, in the 12 years of our lab operation we have Sanger sequenced roughly 8,800 PCR amplicons. Only one error has been identified, and this was due to sequence analysis error.

Our Sanger sequencing is capable of detecting virtually all nucleotide substitutions within the PCR amplicons. Similarly, we detect essentially all heterozygous or homozygous deletions within the amplicons. Homozygous deletions which overlap one or more PCR primer annealing sites are detectable as PCR failure. Heterozygous deletions which overlap one or more PCR primer annealing sites are usually not detected (see Analytical Limitations). All heterozygous insertions within the amplicons up to about 100 nucleotides in length appear to be detectable. Larger heterozygous insertions may not be detected. All homozygous insertions within the amplicons up to about 300 nucleotides in length appear to be detectable. Larger homozygous insertions may masquerade as homozygous deletions (PCR failure).

Analytical Limitations

In exons where our sequencing did not reveal any variation between the two alleles, we cannot be certain that we were able to PCR amplify both of the patient’s alleles. Occasionally, a patient may carry an allele which does not amplify, due for example to a deletion or a large insertion. In these cases, the report contains no information about the second allele.

Similarly, our sequencing tests have almost no power to detect duplications, triplications, etc. of the gene sequences.

In most cases, only the indicated exons and roughly 20 bp of flanking non-coding sequence on each side are analyzed. Test reports contain little or no information about other portions of the gene, including many regulatory regions.

In nearly all cases, we are unable to determine the phase of sequence variants. In particular, when we find two likely causative mutations for recessive disorders, we cannot be certain that the mutations are on different alleles.

Our ability to detect minor sequence variants, due for example to somatic mosaicism is limited. Sequence variants that are present in less than 50% of the patient’s nucleated cells may not be detected.

Runs of mononucleotide repeats (eg (A)n or (T)n) with n >8 in the reference sequence are generally not analyzed because of strand slippage during PCR and cycle sequencing.

Unless otherwise indicated, the sequence data that we report are based on DNA isolated from a specific tissue (usually leukocytes). Test reports contain no information about gene sequences in other tissues.

Deletion/Duplication Testing Via Array Comparative Genomic Hybridization

Test Procedure

Equal amounts of genomic DNA from the patient and a gender matched reference sample are amplified and labeled with Cy3 and Cy5 dyes, respectively. To prevent any sample cross contamination, a unique sample tracking control is added into each patient sample. Each labeled patient product is then purified, quantified, and combined with the same amount of reference product. The combined sample is loaded onto the designed array and hybridized for at least 22-42 hours at 65°C. Arrays are then washed and scanned immediately with 2.5 µM resolution. Only data for the gene(s) of interest for each patient are extracted and analyzed.

Analytical Validity

PreventionGenetics' high density gene-centric custom designed aCGH enables the detection of relatively small deletions and duplications within a single exon of a given gene or deletions and duplications encompassing the entire gene. PreventionGenetics has established and verified this test's accuracy and precision.

Analytical Limitations

Our dense probe coverage may allow detection of deletions/duplications down to 100 bp; however due to limitations and probe spacing this cannot be guaranteed across all exons of all genes. Therefore, some copy number changes smaller than 100-300 bp within a targeted large exon may not be detected by our array.

This array may not detect deletions and duplications present at low levels of mosaicism or those present in genes that have pseudogene copies or repeats elsewhere in the genome.

aCGH will not detect balanced translocations, inversions, or point mutations that may be responsible for the clinical phenotype.

Breakpoints, if occurring outside the targeted gene, may be hard to define.

The sensitivity of this assay may be reduced when DNA is extracted by an outside laboratory.

Order Kits

Ordering Options


myPrevent - Online Ordering
  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
REQUISITION FORM
  • The first four pages of the requisition form must accompany all specimens.
  • Billing information is on the third and fourth pages.
  • Specimen and shipping instructions are listed on the fifth and sixth pages.
  • All testing must be ordered by a qualified healthcare provider.

SPECIMEN TYPES
WHOLE BLOOD

(Delivery accepted Monday - Saturday)

  • Collect 3-5 ml (5 ml preferred) of whole blood in EDTA (purple top tube) or ACD (yellow top tube). For Test #500-DNA Banking only, collect 10-20 ml of whole blood.
  • For small babies, we require a minimum of 1 ml of blood.
  • Only one blood tube is required for multiple tests.
  • Ship blood tubes at room temperature in an insulated container. Do not freeze blood.
  • During hot weather, include a frozen ice pack in the shipping container. Place a paper towel or other thin material between the ice pack and the blood tube.
  • In cold weather, include an unfrozen ice pack in the shipping container as insulation.
  • At room temperature, blood specimen is good for up to 48 hours.
  • If refrigerated, blood specimen is good for up to one week.
  • Label the tube with the patient name, date of birth and/or ID number.

DNA

(Delivery accepted Monday - Saturday)

  • NextGen Sequencing Tests: Send in screw cap tube at least 10 µg of purified DNA at a concentration of at least 50 µg/ml
  • Sanger Sequencing Tests: Send in a screw cap tube at least 15 µg of purified DNA at a concentration of at least 20 µg/ml. For tests involving the sequencing of more than three genes, send an additional 5 µg DNA per gene. DNA may be shipped at room temperature.
  • Deletion/Duplication via aCGH: Send in screw cap tube at least 1 µg of purified DNA at a concentration of at least 100 µg/ml.
  • Whole-Genome Chromosomal Microarray: Collect at least 5 µg of DNA in TE (10 mM Tris-cl pH 8.0, 1mM EDTA), dissolved in 200 µl at a concentration of at least 100 ng/ul (indicate concentration on tube label). DNA extracted using a column-based method (Qiagen) or bead-based technology is preferred.

CELL CULTURE

(Delivery accepted Monday - Thursday)

  • PreventionGenetics should be notified in advance of arrival of a cell culture.
  • Ship at least two T25 flasks of confluent cells.
  • Label the flasks with the patient name, date of birth, and/or ID number.
  • We do not culture cells.